CN105996027B - 一种护肝明目的功能食品 - Google Patents
一种护肝明目的功能食品 Download PDFInfo
- Publication number
- CN105996027B CN105996027B CN201610320956.9A CN201610320956A CN105996027B CN 105996027 B CN105996027 B CN 105996027B CN 201610320956 A CN201610320956 A CN 201610320956A CN 105996027 B CN105996027 B CN 105996027B
- Authority
- CN
- China
- Prior art keywords
- weight
- eyesight
- functional food
- liver
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 210000004185 liver Anatomy 0.000 title claims abstract description 49
- 230000004438 eyesight Effects 0.000 title claims abstract description 36
- 235000013376 functional food Nutrition 0.000 title claims abstract description 26
- SJWWTRQNNRNTPU-ABBNZJFMSA-N fucoxanthin Chemical compound C[C@@]1(O)C[C@@H](OC(=O)C)CC(C)(C)C1=C=C\C(C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)C(=O)C[C@]1(C(C[C@H](O)C2)(C)C)[C@]2(C)O1 SJWWTRQNNRNTPU-ABBNZJFMSA-N 0.000 claims abstract description 35
- AQLRNQCFQNNMJA-UHFFFAOYSA-N fucoxanthin Natural products CC(=O)OC1CC(C)(C)C(=C=CC(=CC=CC(=CC=CC=C(/C)C=CC=C(/C)C(=O)CC23OC2(C)CC(O)CC3(C)C)C)CO)C(C)(O)C1 AQLRNQCFQNNMJA-UHFFFAOYSA-N 0.000 claims abstract description 35
- 150000008442 polyphenolic compounds Chemical class 0.000 claims abstract description 32
- 235000013824 polyphenols Nutrition 0.000 claims abstract description 32
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims abstract description 30
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 claims abstract description 28
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 18
- 229930003427 Vitamin E Natural products 0.000 claims abstract description 15
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims abstract description 15
- 235000019165 vitamin E Nutrition 0.000 claims abstract description 15
- 229940046009 vitamin E Drugs 0.000 claims abstract description 15
- 239000011709 vitamin E Substances 0.000 claims abstract description 15
- JEBFVOLFMLUKLF-IFPLVEIFSA-N Astaxanthin Natural products CC(=C/C=C/C(=C/C=C/C1=C(C)C(=O)C(O)CC1(C)C)/C)C=CC=C(/C)C=CC=C(/C)C=CC2=C(C)C(=O)C(O)CC2(C)C JEBFVOLFMLUKLF-IFPLVEIFSA-N 0.000 claims abstract description 14
- 235000013793 astaxanthin Nutrition 0.000 claims abstract description 14
- 229940022405 astaxanthin Drugs 0.000 claims abstract description 14
- MQZIGYBFDRPAKN-ZWAPEEGVSA-N astaxanthin Chemical compound C([C@H](O)C(=O)C=1C)C(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)C(=O)[C@@H](O)CC1(C)C MQZIGYBFDRPAKN-ZWAPEEGVSA-N 0.000 claims abstract description 14
- 239000001168 astaxanthin Substances 0.000 claims abstract description 14
- 229960003080 taurine Drugs 0.000 claims abstract description 14
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 9
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 9
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 9
- 239000011718 vitamin C Substances 0.000 claims abstract description 9
- 235000013361 beverage Nutrition 0.000 claims abstract description 5
- 239000002775 capsule Substances 0.000 claims abstract description 5
- 241001474374 Blennius Species 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 8
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims description 5
- 241000195493 Cryptophyta Species 0.000 claims description 4
- 241000512259 Ascophyllum nodosum Species 0.000 claims description 2
- 241001428166 Eucheuma Species 0.000 claims description 2
- 241000227647 Fucus vesiculosus Species 0.000 claims description 2
- 241000593522 Sargassum thunbergii Species 0.000 claims description 2
- 241000737023 Zebrasoma flavescens Species 0.000 claims description 2
- 239000003795 chemical substances by application Substances 0.000 claims description 2
- 241001494479 Pecora Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 238000005469 granulation Methods 0.000 abstract description 3
- 230000003179 granulation Effects 0.000 abstract description 3
- 230000037356 lipid metabolism Effects 0.000 abstract description 3
- 238000005516 engineering process Methods 0.000 abstract description 2
- 230000001954 sterilising effect Effects 0.000 abstract description 2
- 238000004659 sterilization and disinfection Methods 0.000 abstract description 2
- 229940100688 oral solution Drugs 0.000 abstract 1
- 230000006870 function Effects 0.000 description 21
- 241000699666 Mus <mouse, genus> Species 0.000 description 18
- 241000283973 Oryctolagus cuniculus Species 0.000 description 16
- 241000700112 Chinchilla Species 0.000 description 15
- 238000005286 illumination Methods 0.000 description 14
- 238000010171 animal model Methods 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 238000011049 filling Methods 0.000 description 10
- 239000004615 ingredient Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 8
- 210000001525 retina Anatomy 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 230000001575 pathological effect Effects 0.000 description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 230000003078 antioxidant effect Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000004300 dark adaptation Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 230000002207 retinal effect Effects 0.000 description 4
- 230000002195 synergetic effect Effects 0.000 description 4
- 210000001519 tissue Anatomy 0.000 description 4
- 238000009423 ventilation Methods 0.000 description 4
- 208000004930 Fatty Liver Diseases 0.000 description 3
- 206010019708 Hepatic steatosis Diseases 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 206010057430 Retinal injury Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000008367 deionised water Substances 0.000 description 3
- 229910021641 deionized water Inorganic materials 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 208000010706 fatty liver disease Diseases 0.000 description 3
- 244000144993 groups of animals Species 0.000 description 3
- 230000002440 hepatic effect Effects 0.000 description 3
- 208000014674 injury Diseases 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000005228 liver tissue Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000003672 processing method Methods 0.000 description 3
- 231100000240 steatosis hepatitis Toxicity 0.000 description 3
- 208000004611 Abdominal Obesity Diseases 0.000 description 2
- 206010065941 Central obesity Diseases 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 208000006550 Mydriasis Diseases 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- BGDKAVGWHJFAGW-UHFFFAOYSA-N Tropicamide Chemical compound C=1C=CC=CC=1C(CO)C(=O)N(CC)CC1=CC=NC=C1 BGDKAVGWHJFAGW-UHFFFAOYSA-N 0.000 description 2
- 230000003044 adaptive effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 229940099352 cholate Drugs 0.000 description 2
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 239000003889 eye drop Substances 0.000 description 2
- 229940012356 eye drops Drugs 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 210000003494 hepatocyte Anatomy 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000004243 retinal function Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229940032021 tetramune Drugs 0.000 description 2
- 229960004791 tropicamide Drugs 0.000 description 2
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 2
- LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 1
- CODAYFPFZXWNLD-UHFFFAOYSA-N 2-hydroxypropanoyl octadecanoate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC(=O)C(C)O CODAYFPFZXWNLD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 238000013218 HFD mouse model Methods 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000001145 Metabolic Syndrome Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- NPGIHFRTRXVWOY-UHFFFAOYSA-N Oil red O Chemical compound Cc1ccc(C)c(c1)N=Nc1cc(C)c(cc1C)N=Nc1c(O)ccc2ccccc12 NPGIHFRTRXVWOY-UHFFFAOYSA-N 0.000 description 1
- 208000017442 Retinal disease Diseases 0.000 description 1
- 206010038923 Retinopathy Diseases 0.000 description 1
- 241000195474 Sargassum Species 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000003464 asthenopia Diseases 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000008021 deposition Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 210000003981 ectoderm Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000000574 ganglionic effect Effects 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 231100000753 hepatic injury Toxicity 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 230000006372 lipid accumulation Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000003170 nutritional factors Nutrition 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 210000001328 optic nerve Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001044 red dye Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000003716 rejuvenation Effects 0.000 description 1
- 230000035806 respiratory chain Effects 0.000 description 1
- 230000033764 rhythmic process Effects 0.000 description 1
- 230000024053 secondary metabolic process Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000007779 soft material Substances 0.000 description 1
- 239000011122 softwood Substances 0.000 description 1
- 229940083466 soybean lecithin Drugs 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- -1 sucrose ester Chemical class 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000001228 trophic effect Effects 0.000 description 1
- 210000003934 vacuole Anatomy 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Their preparation
- A23L2/38—Other non-alcoholic beverages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/336—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having three-membered rings, e.g. oxirane, fumagillin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
- A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
- A61K31/355—Tocopherols, e.g. vitamin E
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/03—Phaeophycota or phaeophyta (brown algae), e.g. Fucus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/02—Algae
- A61K36/04—Rhodophycota or rhodophyta (red algae), e.g. Porphyra
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了一种护肝明目的功能食品。由海藻多酚40‑60重量份、岩藻黄素30‑50重量份、虾青素10‑20重量份、牛磺酸10‑20重量份、维生素C 0.1‑1重量份、维生素E 0.1‑1重量份经过调配、杀菌、制粒、压片、包装工艺制成。所述功能食品可制成胶囊、片剂、冲剂、口服液或饮料,具有显著的调节肝脏脂代谢、改善视力的功效。
Description
技术领域
本发明涉及保健食品技术领域,尤其涉及一种护肝明目的功能食品。
背景技术
近年来,由于人们高度紧张的工作节奏,以及不合理的饮食结构和生活方式,非酒精性脂肪肝(non-alcoholic fatty liver disease,NAFLD)人群越来越多。调查发现,NAFLD的发病率在美国、日本及中国分别达到了33%、29%和10%,且发病年龄有年轻化的趋势(Farrell et al.,2006)。NAFLD属于代谢综合症范畴,与中心性肥胖、高血脂、高甘油三酯血症、Ⅱ型糖尿病、动脉粥样硬化等疾病都有密切关系(Matthew et al.,2007)。据调查,30%的肥胖人群、50%的Ⅱ型糖尿病患者、100%的中心性肥胖症患者均同时患有NAFLD(Shivakumar et al.,2011)。与此同时,患有脂肪肝的人群往往也是视健康问题较为突出的人群。中医学认为,“肝开窍于目,若肝血不足,则易使两目干涩,视物昏花”。说明视疲劳与肝损伤之间具有密切的联系。因此,根据中医多靶点、协同保护的辩证思想,将具有保肝功能的膳食营养因子与视力保护营养因子进行科学组方设计,对改善当前突出的脂肪肝及视力损伤问题能够起到事半功倍的效果。
海藻是海洋植物多酚的主要来源,其结构与陆源植物多酚存在很大不同,现有研究仅局限于抗氧化、抗菌活性的研究。岩藻黄素是褐藻适应海洋极端光环境的次生代谢产物。现有研究表明,岩藻黄素不仅具有突出的抗氧化活性(其抗氧化活性达到维生素E的13.5倍),还具有减肥、抗肿瘤、预防心血管疾病、降血糖、抗炎等多种生理活性。但是,有关岩藻黄素明目功能研究及相关产品开发尚未见报道。此外,牛磺酸可靶向促进呼吸链作用,具有显著的抗疲劳功能;虾青素具有突出的促进胆固醇转运和排泄的功能;维生素C和维生素E则可促进功能成分再生,提高各成分间的协同增效的效果。因此,充分利用传统中医理论的“多途径、多靶点、协同作用”思想,将具有不同功能与作用途径的海藻多酚、岩藻黄素、虾青素、牛磺酸、维生素C、维生素E进行科学组方设计,实现各成分的功效互补,从而得到兼具清肝明目功能的、效果突出的功能食品。目前,尚未见以上成分配伍设计的功能食品。
发明内容
本发明的目的在于提供一种功效明显、绿色天然、适合广大消费群体的护肝明目的功能食品。
为实现上述目的,本发明提供一种护肝明目的功能食品,其特征在于,由海藻多酚40-60重量份、岩藻黄素30-50重量份、虾青素10-20重量份、牛磺酸10-20重量份、维生素C0.1-1重量、维生素E 0.1-1重量份制备得到。
进一步,所述海藻多酚中总酚重量含量不少于20%。
进一步,所述岩藻黄素中岩藻黄素重量含量不少于10%。
进一步,所述海藻多酚和岩藻黄素来源于可食用海藻。
进一步,所述可食用海藻为海带、紫菜、羊栖菜、裙带菜、鼠尾藻、红毛藻、泡叶藻、麒麟菜、江蓠、墨角藻或微球藻。
进一步,所述清肝明目的功能食品是片剂、胶囊或冲剂。
进一步,所述清肝明目的功能食品是休闲食品或饮料。
所述海藻多酚是按本发明人前期已申请受理发明专利“一种高纯度海藻多酚的制备方法”(专利受理公开号:CN105193863A)记载的方法进行制备的。
所述岩藻黄素是按本发明人前期已授权发明专利“一种酶法制备褐藻岩藻聚糖与岩藻黄素的方法”(专利号:ZL201310142757.X)记载的方法进行制备的。
所述功能食品配方中的活性成分是由海藻多酚、岩藻黄素、虾青素、牛磺酸、维生素C和维生素E按一定比例构成的。申请人首先通过高脂诱导小鼠非酒精性脂肪肝动物学实验及可见光诱导青紫蓝兔视网膜损伤动物模型证实(实验内容见实施例6,结果如表1所示),海藻多酚不仅具有突出的调节肝脏脂代谢功能,也能适当改善视网膜功能,其有效剂量范围为80mg/kg-120mg/kg;岩藻黄素则以突出的视网膜保护功能为主,兼具降脂保肝的功效,有效剂量范围为60mg/kg-100mg/kg。该结果说明,海藻多酚与岩藻黄素在护肝明目功能食品中具有良好的功效互补作用。尽管海藻多酚和岩藻黄素在有效剂量范围分别具有良好的护肝和视力保护功能,但效果依然不够理想。
表1 海藻多酚、岩藻黄素有效剂量确定表
因此,产品在以海藻多酚和岩藻黄素为主的基础上,进一步结合中医理论的“多靶点、协同作用”理论,科学选取牛磺酸、虾青素、维生素C(Vc)和维生素E(VE)与之配伍,使产品护肝明目功能的进一步提升。选取以上成分的理论依据在于:牛磺酸既能促进肝糖原的从头合成,促进脂肪酸的β-氧化途径,减少肝脏中的脂质累积,也是促进视神经生长发育、保护视网膜的重要营养素;虾青素不仅能够降低肝脏胆固醇的合成,对视力也有保护作用;维生素C和维生素E也是视网膜必须的营养素,在抗氧化方面具有典型的协同增效功能。采用前述高脂诱导小鼠非酒精性脂肪肝动物学实验及可见光诱导青紫蓝兔视网膜损伤动物模型,灌胃剂量为200mg/kg,以海藻多酚、岩藻黄素的最低有效剂量为基础,进一步进行组方优选,实验结果如表2所示。在海藻多酚与岩藻黄素保持最低有效剂量的基础上(40wt%和30wt%),进一步与牛黄酸、虾青素、维生素C和维生素E配伍的效果最佳,减少某种成分均会导致功能降低。同时,结果发现牛黄酸、虾青素、维生素C和维生素E的最佳重量比分别为10wt%-20wt%、10wt%-20wt%、0.1wt%-1wt%和0.1wt%-1wt%,改变上述比例均导致功效性变差。
表2 各组分不同配比的功效对比表(剂量:200mg/kg)
本发明的发明人将以上成分进行科学配比设计,使各组合物具有显著的协同增效的作用,从而提高产品的功能。因此,本发明中强调这六种成分在产品中所占的比例。
附图说明
图1是实施例5模型对照组小鼠肝组织病理切片图(×400)。
图2是实施例5组方干预组小鼠肝组织病理切片图(×400)。
图3是实施例5组方干预组青紫蓝兔视网膜组织病理切片图(×400)。
具体实施方式
下面详细描述本发明的实施例,所述实施例的示例在附图中示出,其中自始至终相同或类似的标号表示相同或类似的元件或具有相同或类似功能的元件。下面通过参考附图描述的实施例是示例性的,旨在用于解释本发明,而不能理解为对本发明的限制。实施例中未注明具体技术或条件者,按照本领域内的文献所描述的技术或条件或者按照产品说明书进行。所用试剂或仪器未注明生产厂商者,均为可以通过市购获得的常规产品。
实施例1:护肝明目的胶囊
以海藻多酚40重量份、岩藻黄素30重量份、虾青素10重量份、牛磺酸10重量份、维生素C 0.1重量份、维生素E 0.1重量份的比例称取上述各提取物,组方中加入适量硬脂酸镁和淀粉,混匀,用全自动胶囊填充机填充入硬胶囊,每粒装量0.5g,即得胶囊类护肝明目的功能食品。
实施例2:护肝明目的片剂
以海藻多酚50重量份、岩藻黄素40重量份、虾青素15重量份、牛磺酸15重量份、维生素C 0.5重量份、维生素E 0.5重量份的比例称取上述各提取物,配方加入适量的糊精、淀粉、微晶纤维素和乳糖中的一种或几种辅料,混合均匀,用适量70%(v/v)乙醇润湿,制软材,过30目筛制粒,于70-80℃干燥,用60目筛整粒,压片,得片剂,每片0.2g,即得片剂类护肝明目的功能食品。
实施例3:护肝明目的冲剂
以海藻多酚55重量份、岩藻黄素45重量份、虾青素15重量份、牛磺酸15重量份、维生素C 0.5重量份、维生素E 0.5重量份的比例称取上述各提取物,组方中加入适量可溶性淀粉、糊精、蔗糖、乳糖和甘露醇其中一种或几种,用适量70%(v/v)乙醇润湿,制软材,过20目筛制粒,70-80℃干燥,60目整粒,即得冲剂类护肝明目的功能食品。
实施例4:护肝明目的饮料
以海藻多酚60重量份、岩藻黄素50重量份、虾青素20重量份、牛磺酸20重量份、维生素C 1重量份、维生素E 1重量份的比例称取上述各提取物,配方溶于适量的70%(v/v)乙醇,加入大豆卵磷脂、硬脂酰乳酸钠、三聚甘油酯、蔗糖酯、月桂酸单甘油酯中的一种或几种进行乳化,然后经复溶、加入适量的甜味剂和稳定剂,混匀,过滤,灌装,杀菌,即得饮料类护肝明目的功能食品。
实施例5:效果验证实验
1)护肝验证实验
将实施例1中得到的配方设置为组方干预组,并设置空白对照组,模型对照组。
实验动物:SPF级雌性ICR小鼠,15-20g,购于上海斯莱克实验动物有限责任公司。小鼠基础饲料成分:碳水化合物64%,蛋白质21%,脂肪4%,纤维5%,水分6%;小鼠高脂饲料成分:10%猪油,1%胆固醇,0.1%胆酸盐和88.9%基础饲料。上述饲料均购于上海斯莱克实验动物有限责任公司。饲养室温度:23±2℃,相对湿度55±5%。
剂量的确定:配方灌胃的剂量为200mg/kg。
动物分组及处理方法:小鼠适应性喂养1周后,按照体重随机分为6组,每组10只,空白对照组给予基础饲料,模型对照组、阳性对照组及组方干预组均给予高脂饲料,自由采食。组方干预组每日灌胃实施例1所得200mg/kg。每3天称一次体重,根据体重变化调整给药量。给药时,将实施例1所得产品用去离子水配置成液体状后,按剂量经口灌胃。饲喂8周实验结束时,处死小鼠摘取小鼠肝脏,一部分用于制作肝冷冻切片,其余用于测定肝脏TC、TG、LDL和HDL含量。
实验结果:
从表3可以看出,经过8周的高脂饲料喂养,模型对照组小鼠肝脏中TC、TG、LDL和HDL含量均显著高于空白对照组(P<0.05),这说明模型组小鼠的肝脏已经出现了明显的脂质异常堆积,出现了非酒精性脂肪肝症状。经组方产品干预后,肝脏中TC、TG、LDL和HDL水平出现了显著降低,说明组方产品具有明显的护肝功能。
表3 配方对高脂饮食小鼠肝脏脂质指标的影响表(n=10)
肝组织病理切片观察:经过8周的试验,各组小鼠肝脏进行油红O染色,观察肝细胞脂肪沉积情况。结果显示:模型对照组肝细胞肿胀,肝窦消失,胞浆内可见大小不一的圆形空泡,胞核居中或偏向一侧,出现散在肝细胞脂肪变性(见图1,图1是模型对照组小鼠肝组织病理切片图);组方干预组呈肝细胞内未见明显红染脂肪滴,肝细胞脂肪变性出现明显好转(见图2,图2是组方干预组小鼠肝组织病理切片图)。以上说明产品具有良好的护肝功能。
2)视力保护功能评价实验
实验动物及饲养环境:SPF级青紫蓝兔,雌雄各半,体重2.0±0.2kg,由北京天坛生物制品股份有限公司动物中心提供(合格证号为SCXK(京)2004-0002)。室内通风条件良好,正常昼夜变化(8:00am-8:00pm),相对湿度为55±5%,室温:23±2℃。
剂量确定:配方灌胃的剂量为200mg/kg
实验方法:21只青紫蓝兔适应性饲养一周,自由采食。1周后按体重随机分成3组,即空白对照组,模型对照组,组方干预组,每组7只试验动物。按以下剂量继续饲喂2周:空白对照组每日灌胃剂量为2.5mL水,模型组每日灌胃剂量为2.5mL水,组方干预组每日灌胃剂量为400mg样品(实施例1所得)。2周后,进行光照实验。光照实验采用自制光照箱:光照箱尺寸为50×40×30cm,底面和四周均为镜子,侧面四个角上各安装一根白色冷光源荧光灯管,使得光照箱内各方向光照度均为15000±1000lux(TES-1332A照度计测定)。模型对照组、组方干预组青紫蓝兔于60-100lux光环境中暗适应处理24h后,采用复方托吡卡胺滴眼液对双眼进行散瞳,20min后置于自制光照箱中开始光照,每个光照箱中内放置一只青紫蓝兔,光照2h,不限制青紫蓝兔活动。整个光照过程保持通风,保证光照箱内温度保持在21-24℃的相对恒温环境。光照处理结束后,试验动物送回动物房中进行暗适应处理。按前述灌胃剂量及采食方式继续饲养各组动物7天,然后采用病理切片观察视网膜病变情况。
实验结果:青紫蓝兔视网膜组织学病理切片如图3所示,其中图3是组方干预组青紫蓝兔视网膜组织病理切片图。空白对照组视网膜细胞层次分明,感光细胞内外层排列紧密、分界清晰;模型对照组视网膜细胞出现了大量凋亡,感光细胞内外节层次模糊,说明视网膜受到了明显的光损伤;经组方干预后,由图可看出,青紫蓝兔视网膜组织形态正常,结构层次清晰,内外节排列整齐规则,内外细胞层分界清晰,证明产品具有良好的保护视网膜光损伤的功效。
采用实施例2-4所得进行效果验证,具有与实施例1同样良好的护肝功能和保护视网膜光损伤的效果。
实施例6:高脂诱导小鼠非酒精性脂肪肝动物学实验和可见光诱导青紫蓝兔视网膜损伤动物模型
(1)高脂诱导小鼠非酒精性脂肪肝动物学实验
实验动物:SPF级雌性ICR小鼠,15-20g,购于上海斯莱克实验动物有限责任公司。小鼠基础饲料成分:碳水化合物64%,蛋白质21%,脂肪4%,纤维5%,水分6%;小鼠高脂饲料成分:10%猪油,1%胆固醇,0.1%胆酸盐和88.9%基础饲料。上述饲料均购于上海斯莱克实验动物有限责任公司。饲养室温度:23±2℃,相对湿度55±5%。
给药剂量及方法:海藻多酚的灌胃的剂量分别为60mg/kg、80mg/kg、100mg/kg、120mg/kg和140mg/kg;岩藻黄素的灌胃的剂量分别为40mg/kg、60mg/kg、80mg/kg、100mg/kg和120mg/kg。
动物分组及处理方法:小鼠适应性喂养1周后,按照体重随机分为6组,每组10只,除正常组给予基础饲料外,其余组均给予高脂饲料,自由采食。每3天称一次体重,根据体重变化调整给药量。给药时,将海藻多酚用去离子水配置成液体状后,按剂量经口灌胃。连续8周给药后处死小鼠,摘取小鼠肝脏,于含冰的生理盐水中快速漂洗,拭干,用于测定肝脏总胆固醇(TC)含量。
(2)可见光诱导青紫蓝兔视网膜损伤动物模型
实验动物及饲养环境:SPF级青紫蓝兔,雌雄各半,体重2.0±0.2kg,由北京天坛生物制品股份有限公司动物中心提供(合格证号为SCXK(京)2004-0002)。室内通风条件良好,正常昼夜变化(8:00am-8:00pm),相对湿度为55±5%,室温:23±2℃。
给药剂量及方法:海藻多酚的灌胃的剂量分别为60mg/kg、80mg/kg、100mg/kg、120mg/kg和140mg/kg;岩藻黄素的灌胃的剂量分别为40mg/kg、60mg/kg、80mg/kg、100mg/kg和120mg/kg。
动物分组及处理方法:青紫蓝兔适应性饲养一周,自由采食。1周后按体重随机分成12组,即正常组,模型组,5个海藻多酚不同剂量干预组,5个岩藻黄素不同剂量干预组,每组7只试验动物。按以下剂量继续饲喂2周:正常组每日灌胃剂量为2.5mL水,模型组每日灌胃剂量为2.5mL水;分别将海藻多酚及岩藻黄素用去离子水配置成液体状后,按剂量经口灌胃。2周后,进行光照实验。光照实验采用自制光照箱:光照箱尺寸为50×40×30cm,底面和四周均为镜子,侧面四个角上各安装一根白色冷光源荧光灯管,使得光照箱内各方向光照度均为15000±1000lux(TES-1332A照度计测定)。模型组、海藻多酚干预组、岩藻黄素干预组青紫蓝兔于60-100lux光环境中暗适应处理24h后,采用复方托吡卡胺滴眼液对双眼进行散瞳,20min后置于自制光照箱中开始光照,每个光照箱中内放置一只青紫蓝兔,光照2h,不限制青紫蓝兔活动。整个光照过程保持通风,保证光照箱内温度保持在21-24℃的相对恒温环境。光照处理结束后,试验动物送回动物房中进行暗适应处理。按前述灌胃剂量及采食方式继续饲养各组动物7天,然后采用电视觉生理仪ERG检测各组动物视网膜最大混合反应ERG值。
从发明内容部分的表1数据可以看出,海藻多酚不仅具有突出的调节肝脏脂代谢功能,也能适当改善视网膜功能,其有效剂量范围为80mg/kg-120mg/kg;岩藻黄素则以突出的视网膜保护功能为主,兼具降脂保肝的功效,有效剂量范围为60mg/kg-100mg/kg。该结果说明,海藻多酚与岩藻黄素在护肝明目功能食品中具有良好的功效互补作用。尽管海藻多酚和岩藻黄素在有效剂量范围分别具有良好的护肝和视力保护功能,但效果依然不够理想。
尽管上面已经示出和描述了本发明的实施例,可以理解的是,上述实施例是示例性的,不能理解为对本发明的限制,本领域的普通技术人员在不脱离本发明的原理和宗旨的情况下在本发明的范围内可以对上述实施例进行变化、修改、替换和变型。
Claims (7)
1.一种护肝明目的功能食品,其特征在于,由海藻多酚40-60重量份、岩藻黄素30-50重量份、虾青素10-20重量份、牛磺酸10-20重量份、维生素C 0.1-1重量、维生素E 0.1-1重量份制备得到。
2.权利要求1所述护肝明目的功能食品,其特征在于,所述海藻多酚中总酚重量含量不少于20%。
3.权利要求1所述护肝明目的功能食品,其特征在于,所述岩藻黄素中岩藻黄素重量含量不少于10%。
4.权利要求1所述护肝明目的功能食品,其特征在于,所述海藻多酚和岩藻黄素来源于可食用海藻。
5.权利要求4所述护肝明目的功能食品,其特征在于,所述可食用海藻为海带、紫菜、羊栖菜、裙带菜、鼠尾藻、红毛藻、泡叶藻、麒麟菜、江蓠、墨角藻或微球藻。
6.权利要求1所述护肝明目的功能食品,其特征在于,所述护肝明目的功能食品是片剂、 胶囊或冲剂。
7.权利要求1所述护肝明目的功能食品,其特征在于,所述护肝明目的功能食品是休闲食品或饮料。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201610299322X | 2016-05-07 | ||
CN201610299322 | 2016-05-07 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN105996027A CN105996027A (zh) | 2016-10-12 |
CN105996027B true CN105996027B (zh) | 2019-05-10 |
Family
ID=57097670
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201610320956.9A Active CN105996027B (zh) | 2016-05-07 | 2016-05-14 | 一种护肝明目的功能食品 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN105996027B (zh) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109007225A (zh) * | 2018-10-16 | 2018-12-18 | 云南爱尔康生物技术有限公司 | 一种褐藻虾青素压片糖果及其制备方法 |
CN109757723B (zh) * | 2019-01-25 | 2022-07-01 | 集美大学 | 一种含岩藻黄醇的视力保护功能食品及其制备方法 |
CN109805375B (zh) * | 2019-01-28 | 2022-05-17 | 集美大学 | 一种提高视器官抗氧化能力的功能食品及其制备方法 |
CN112870331B (zh) * | 2021-02-23 | 2021-10-15 | 广东海洋大学 | 一种防治酒精性肝损伤的组合物及其制备方法与应用 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101306009A (zh) * | 2008-06-06 | 2008-11-19 | 广州蓝钥匙海洋生物工程有限公司 | 一种用于护肝养肝的功能食品 |
CN102334688A (zh) * | 2011-07-21 | 2012-02-01 | 秦皇岛大惠生物技术有限公司 | 一种具有减脂功能的保健食品 |
CN105037300A (zh) * | 2015-06-17 | 2015-11-11 | 宁波大学 | 一种从马尾藻中综合提取岩藻黄素和褐藻多酚的方法 |
CN105193863A (zh) * | 2015-10-09 | 2015-12-30 | 集美大学 | 一种高纯度海藻多酚的制备方法 |
CN106083765A (zh) * | 2016-05-26 | 2016-11-09 | 深圳市海立方生物科技有限公司 | 一种具有抗菌功能的环保安全清洗剂 |
-
2016
- 2016-05-14 CN CN201610320956.9A patent/CN105996027B/zh active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101306009A (zh) * | 2008-06-06 | 2008-11-19 | 广州蓝钥匙海洋生物工程有限公司 | 一种用于护肝养肝的功能食品 |
CN102334688A (zh) * | 2011-07-21 | 2012-02-01 | 秦皇岛大惠生物技术有限公司 | 一种具有减脂功能的保健食品 |
CN105037300A (zh) * | 2015-06-17 | 2015-11-11 | 宁波大学 | 一种从马尾藻中综合提取岩藻黄素和褐藻多酚的方法 |
CN105193863A (zh) * | 2015-10-09 | 2015-12-30 | 集美大学 | 一种高纯度海藻多酚的制备方法 |
CN106083765A (zh) * | 2016-05-26 | 2016-11-09 | 深圳市海立方生物科技有限公司 | 一种具有抗菌功能的环保安全清洗剂 |
Non-Patent Citations (1)
Title |
---|
Protective Effect of Fucoxanthin Isolated from Laminaria japonica against Visible Light-Induced Retinal Damage Both in Vitro and in Vivo;Yixiang Liu 等;《J Agric Food Chem》;20160120;416-424 |
Also Published As
Publication number | Publication date |
---|---|
CN105996027A (zh) | 2016-10-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2017101389A4 (en) | Specialized flour for nutrition meals for diabetes and preparation method and use thereof | |
CN105996027B (zh) | 一种护肝明目的功能食品 | |
CN103734712B (zh) | 一种护眼蓝莓和树莓功能食品 | |
US9889173B2 (en) | Composition for improving macular pigment density and preventing or treating age-related macular degeneration | |
EP2138055B1 (en) | Formula food to be beneficial for visuognosis persistence and use thereof | |
CN102763847B (zh) | 一种具有缓解视疲劳的保健食品及其制备方法 | |
CN103238897A (zh) | 一种适用于糖尿病人的复合植物固体饮料 | |
CN104432036B (zh) | 缓解视疲劳的保健营养组合物及其制备方法与应用 | |
CN103735733A (zh) | 一种含叶黄素酯的复方制剂及其制备方法 | |
CN101904507B (zh) | 甘氨酸亚铁营养组合物及其应用 | |
CN103300373A (zh) | 叶黄素原花青素复合软胶囊及其制备方法 | |
CN108078972A (zh) | γ-氨基丁酸在制备缓解视疲劳的食品、保健品或药品中的用途 | |
CN108159036A (zh) | 含茶氨酸、磷脂酰丝氨酸和原花青素的缓解视疲劳的组合物 | |
CN108354175A (zh) | 含鱼眼、茶氨酸和γ-氨基丁酸的缓解视疲劳的组合物 | |
CN103798808A (zh) | 一种营养素配方及在缓解视疲劳的食品或药物中的应用 | |
CN108185427A (zh) | 含鱼眼、茶氨酸和磷脂酰丝氨酸的缓解视疲劳的组合物 | |
CN108354918A (zh) | 含茶氨酸、γ-氨基丁酸和原花青素的缓解视疲劳的组合物 | |
CN105852114B (zh) | 一种降脂保肝的功能食品 | |
CN108210640A (zh) | 含茶叶提取物的缓解视疲劳组合物 | |
CN101850028B (zh) | 一种具有缓解视疲劳功能的组合物 | |
CN112042939A (zh) | 一种补充视网膜营养咀嚼片 | |
CN108057074A (zh) | 含枸杞、菊花和茶氨酸的缓解视疲劳的组合物 | |
CN107252038A (zh) | 一种适于糖尿病人群的功能食品 | |
RU2749344C1 (ru) | Способ приготовления халяльных мини пирожков | |
CN108096234A (zh) | 含茶氨酸、磷脂酰丝氨酸和花青素的缓解视疲劳的组合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20221101 Address after: 105, Building 4, Fengqingyuan Business, Lushan, No. 128, Nanyuan Road, Wangchengpo Street, Yuelu District, Changsha City, Hunan Province, 410000 Patentee after: Hunan Bainian Medical Prescription Pharmacy Co.,Ltd. Address before: No. 185 Yinjiang Road, Jimei District, Xiamen City, Fujian Province, 361000 Patentee before: JIMEI University |
|
TR01 | Transfer of patent right |